Quantum Biopharma (QNTM) Net Income towards Common Stockholders (2019 - 2026)
Quantum Biopharma (QNTM) reported Net Income towards Common Stockholders of -$3.0 million for Q1 2026, up 12.67% on a YoY basis from -$2.7 million in Q1 2025, and down 29.92% sequentially from -$2.3 million in Q4 2025.
Quantum Biopharma (QNTM) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Quantum Biopharma (QNTM) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 12.67% year-over-year to -$3.0 million; the trailing twelve-month figure through Mar 2026 stood at -$15.0 million (down 14.1% YoY), and the FY2025 full-year result was -$27.0 million, changed N/A from the prior year.
- Net Income towards Common Stockholders fell to -$3.0 million in Q1 2026, from -$2.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$444506.0 in Q1 2022 to a low of -$9.8 million in Q1 2023.
- A 5-year average of -$3.7 million and a median of -$3.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders slumped 2115.35% in 2023 and soared 76.95% in 2024, its largest moves.
- Tracing QNTM's Net Income towards Common Stockholders over 5 years: stood at -$444506.0 in 2022, then sank by 646.45% to -$3.3 million in 2023, then jumped by 36.91% to -$2.1 million in 2024, then fell by 9.91% to -$2.3 million in 2025, then retreated by 29.92% to -$3.0 million in 2026.
- Business Quant data shows QNTM's Net Income towards Common Stockholders at -$3.0 million in Q1 2026, -$2.3 million in Q4 2025, and -$4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Quantum Biopharma | 13.00 Bn | 13.00 Bn | - | -2.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.99 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -4.77 Mn |
| Jun 30, 2025 | -4.97 Mn |
| Mar 31, 2025 | -3.42 Mn |
| Dec 31, 2024 | -2.09 Mn |
| Sep 30, 2024 | -4.19 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Mar 31, 2024 | -2.27 Mn |
| Sep 30, 2023 | -3.32 Mn |
| Mar 31, 2023 | -9.85 Mn |
| Mar 31, 2022 | -444,506.00 |
| Jun 30, 2021 | -452,937.00 |
| Mar 31, 2021 | 533,842.00 |
| Sep 30, 2020 | -1.16 Mn |
| Jun 30, 2020 | -408,872.15 |
| Mar 31, 2020 | -896,464.60 |
| Dec 31, 2019 | -11.59 Mn |
| Sep 30, 2019 | -1.71 Mn |
| Jun 30, 2019 | -1.18 Mn |